Soliton Receives Additional Patent for Breakthrough Acoustic Shockwave Technology

Rapid Acoustic Pulse device granted patent in China; bringing a total of 38 issued or pending patents


Houston, TX – February 26, 2019 – Soliton, Inc., (Nasdaq: SOLY), (“Soliton” or the “Company”), a medical technology company that has developed a new acoustic shockwave device, today announced that the National Intellectual Property Administration (Chinese Patent Office) has issued a notice of grant for Chinese Patent Application No. 201280041817.2, based on International Application No.PCT/IS2012/046674; Entitled “Apparatus for Generating Therapeutic Shockwaves And Applications of Same,” by Christopher C. Capelli.


Dr. Chris Capelli, CEO of Soliton, said,  “The granting of this patent is an important milestone for Soliton. With the issuance of this patent in the People’s Republic of China (“PRC”) for our leading-edge Rapid Acoustic Pulse (“RAP”) technology and with our pending United States patents, we are well positioned to develop two of the major consumer markets in the world. We have a strong portfolio that now numbers 38 issued and pending patents that we believe provides Soliton a meaningful competitive advantage in removing unwanted tattoos in about one-third of the time of traditional procedures, with less pain and discomfort, and at a lower overall cost.”


Soliton has discovered other capabilities of the RAP technology during preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as potentially reducing the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth.  Importantly, this potential indication could position Soliton RAP as a stand-alone device, without the need for lasers or other procedures.


Dr. Capelli concluded, “If our ongoing clinical trials prove to be effective in cellulite and fat removal, we will dramatically expand our addressable markets. We are excited with the opportunities ahead in the coming years.”



About Soliton, Inc.


Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product will use rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing this device to the market. The Company expects to file for premarket clearance with the U.S. Food and Drug Administration (“FDA”) for its’ first device in the first quarter of 2019 and expects to receive clearance to market the device in mid 2019. This initial filing is limited to the Company’s device used in conjunction with the 1064 nm Q-switched laser to enable effective multiple pass laser treatments in a single office session to accelerate removal of black tattoos on the arms, legs and torso in Fitzpatrick Skin Type I-III individuals. While the Company believes its’ technology has many potential applications, the Company has initially focused on the removal of tattoos, where both animal and human studies have shown promising results. The current standard of care for tattoo removal is to use a Q-switched (pulsed) laser to ablate the tattoo ink particles into pieces small enough for the body’s natural processes to remove them. Unfortunately, this current method is highly inefficient, requiring up to 10 or more office visits to achieve acceptable results. A clinical trial has demonstrated that using the Company’s RAP device, in conjunction with a Q-switched laser, has the potential to produce similar results in just 2 to 3 office visits versus the industry average of 10 or more with a stand-alone laser. The Company believes this “Soliton” method can not only dramatically accelerate tattoo removal, but also has the potential to lower removal cost for patients, while increasing profitability to practitioners, and to reduce the potential for unwanted side effects from current laser removal methods.



For more information about the Company, please visit:


Forward-Looking Statements


Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Soliton RAP to accelerate tattoo fading or fat removal and/or to reduce cellulite, and whether  future clinical trials related to the acceleration of existing fat removal technologies and cellulite are successful. These statements relate to future events, future expectations, plans and prospects. Although Soliton believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Soliton has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under in our SEC filings, including under the heading “Risk Factors” in the Form 1-A we filed with the SEC on February 13, 2019. Any forward-looking statements contained in this release speak only as of its date. Soliton undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.



Joe Dorame, Joe Diaz & Robert Blum

Lytham Partners, LLC



Source:  Soliton, Inc.